Ketamine

Like many highly addictive drugs, ketamine causes a rush of dopamine in the brain. But new research in mice from the University of Geneva shows ketamine also blocks the brain process that leads to neuroplasticity, habit formation and compulsion.

How much of a problem is it if participants in psychedelic clinical trials can easily tell they have been given a placebo? Researcher Suresh Muthukumaraswamy suggests it is, and many findings from recent psychedelic trials may be over-estimated.

A Phase 2 clinical trial has found a single treatment session with nitrous oxide can deliver significant and rapid improvements in patients with treatment-resistant depression, and the research indicates these benefits can last for at least two weeks.

The notion of using ketamine as an anti-depressant is gathering steam, and a new study has shown how this might work in practice, with chronic suicidality sufferers offered rapid relief through oral administration of the drug in clinical settings.

A new pilot study has demonstrated nitrous oxide, commonly known as laughing gas, may help military veterans suffering from PTSD. A larger trial is now underway after several studies demonstrated potential new uses for the gas.

Scientists have discovered a new mechanism to help illustrate the rapid antidepressant qualities of ketamine. Imaging patients with depression revealed ketamine’s effects are a result of its interaction with a particular kind of serotonin receptor.

A study led by scientists at Yale University has described the promising early-stage results of a new drug designed to mimic the rapid antidepressant effects of ketamine, but without that drug’s dissociative psychoactive qualities. The experimental drug is currently in early phases of human testing.

There remains a lot to learn about ketamine and its close chemical relatives when treating depression. A new study has shed more light on how it can stave off depressive symptoms, with experiments on mice revealing how it repairs busted circuits in the brain.​

Following the FDA’s approval of a ketamine-inspired nasal spray for treatment-resistant depression, new research is offering provocative insights into how the drug exerts such a rapid anti-depressant effect and points to new pathways for research into alternative drugs to treat depression.

The FDA has just approved esketamine for adults with treatment-resistant depression, in a landmark announcement marking the first new major depression treatment introduced for clinical use in over 30 years. The nasal spray is a close chemical relative to the controversial anesthetic ketamine.

A new nasal spray for depression, utilizing a drug called esketamine, has passed the last step on its way to final FDA approval. An advisory panel to the FDA voted in favor of the new drug’s risk/benefit profile meaning the ketamine-inspired treatment may be approved for use within the next month.

Two new studies suggest the psychiatric benefits of ketamine treatment may extend beyond just the targeting of depression. The research demonstrates ketamine may be helpful in targeting both anxiety- and substance abuse-related depression.